Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H5N3O3 |
| Molecular Weight | 215.165 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC(C=C(C#N)C#N)=CC=C1[N+]([O-])=O
InChI
InChIKey=DUQADSPERJRQBW-UHFFFAOYSA-N
InChI=1S/C10H5N3O3/c11-5-8(6-12)3-7-1-2-9(13(15)16)10(14)4-7/h1-4,14H
| Molecular Formula | C10H5N3O3 |
| Molecular Weight | 215.165 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
AG-126 is the putative protein tyrosine kinase (PTK) inhibitor. It was found to rescue mice from lethal consequences of bacterial lipopolysaccharide (LPS) administration in a model of septic shock. AG126 treatment has beneficial effects in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. AG126 alleviates the clinical symptoms, diminishes encephalitogenic Th17 differentiation, reduces inflammatory CNS infiltration as well as microglia activation and attenuates myelin damage. AG-126 have recently been shown to protect from acute kidney injury in experimental animal models of ischemia-reperfusion and sepsis-induced injury. AG-126 modulates secondary damage in experimental spinal cord trauma.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: WP2884 |
|||
Target ID: CHEMBL5251 |
|||
Target ID: map04210 |
|||
Target ID: CHEMBL2363049 |
150.0 µM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Regulation of lipopolysaccharide-induced inducible nitric-oxide synthase expression through the nuclear factor-kappaB pathway and interferon-beta/tyrosine kinase 2/Janus tyrosine kinase 2-signal transducer and activator of transcription-1 signaling cascades by 2-naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI 53), a new synthetic isoquinoline alkaloid. | 2007 Feb |
|
| Inhibition of host extracellular signal-regulated kinase (ERK) activation decreases new world alphavirus multiplication in infected cells. | 2014 Nov |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:39:23 GMT 2023
by
admin
on
Fri Dec 15 19:39:23 GMT 2023
|
| Record UNII |
7YA4AMD1JC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7YA4AMD1JC
Created by
admin on Fri Dec 15 19:39:23 GMT 2023 , Edited by admin on Fri Dec 15 19:39:23 GMT 2023
|
PRIMARY | |||
|
DTXSID80152117
Created by
admin on Fri Dec 15 19:39:23 GMT 2023 , Edited by admin on Fri Dec 15 19:39:23 GMT 2023
|
PRIMARY | |||
|
2046
Created by
admin on Fri Dec 15 19:39:23 GMT 2023 , Edited by admin on Fri Dec 15 19:39:23 GMT 2023
|
PRIMARY | |||
|
118409-62-4
Created by
admin on Fri Dec 15 19:39:23 GMT 2023 , Edited by admin on Fri Dec 15 19:39:23 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
